Extreme Price Competition in Pharmaceutical Industry May Put Patients at Serious Health Risk, Study Shows

Amid intense pressure to lower drug prices, policymakers in the pharmaceutical industry have leveraged regulations to increase product competition and lower prices by creating an expedited approval process for generic drugs.

But new research from the University of Notre Dame, Indiana University and the University of Minnesota shows such competition-inducing regulations may encourage companies to relax quality standards during the manufacturing process, which may put more patients at serious health risk due to lower-quality products and more product recalls. It also suggests generic drug makers may be underreporting discretionary recalls due to competitive pressures.

Read more here.

0 Likes

Share